How ALS hasn’t stopped a Dallas Marathon competitor from reaching lofty running heights
Troy Pruett, a Grapevine resident, will be competing in his 96th marathon this weekend and getting one step closer to the ...
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...
STAT20h
They agreed to cover a drug for six months — and now I have to fight for it again
Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...
Private Medicare plans must cover Biogen's ALS drug, US agency says
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Indiana Gazette1d
Community rallies for Blairsville resident with ALS, Bulbar Palsy
It was seven months later when she was diagnosed with amyotrophic lateral sclerosis and bulbar palsy, both neurological ...
Zacks.com on MSN1d
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...
FierceBiotech1d
Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
Business Wire2d
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
The Brighterside of News on MSN2d
Critical link between protein and ALS disease offers new hope
Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...
NeuroSense concludes Type C meeting with FDA for PrimeC treatment
Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...